Showing results (41-50 of 1,146) with videos related to
Sort By:
Pageof 115
The Journal of Clinical Psychiatry|December 4, 2014
Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherenceChristoph U CorrellWorld Psychiatry : Official Journal of the World Psychiatric Association (WPA)|June 7, 2016
Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysisDavy Vancampfort, Christoph U Correll, Britta Galling, et al.World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|January 3, 2019
The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trialsDavy Vancampfort, Joseph Firth, Christoph U Correll, et al.Focus (American Psychiatric Publishing)|September 6, 2021
The Impact of Pharmacological and Non-Pharmacological Interventions to Improve Physical Health Outcomes in People With Schizophrenia: A Meta-Review of Meta-Analyses of Randomized Controlled TrialsDavy Vancampfort, Joseph Firth, Christoph U Correll, et al.Expert Opinion on Investigational Drugs|December 19, 2022
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophreniaMikkel Højlund, Christoph U CorrellThe Journal of Clinical Psychiatry|October 13, 2021
Diagnostic and Treatment Fundamentals for Tardive DyskinesiaChristoph U Correll, Leslie CitromeJournal of the American Academy of Child and Adolescent Psychiatry|January 30, 2014
Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregressionShimon Schwartz, Christoph U CorrellDialogues in Clinical Neuroscience|March 4, 2015
Clinical predictors of therapeutic response to antipsychotics in schizophreniaMaren Carbon, Christoph U CorrellThe Journal of Clinical Psychiatry|August 31, 2021
Measurement-based Diagnosis and Treatment for Tardive DyskinesiaChristoph U Correll, Leslie CitromeExpert Opinion on Drug Metabolism & Toxicology|February 28, 2025
Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophreniaGeorgios Schoretsanitis, Christoph U CorrellPageof 115